Roche's strategy of pursuing a personalized healthcare approach for its oncology drug development has moved on apace with the decision to spend $2.4bn to buy the remainder of molecular information company Foundation Medicine.
The Swiss major acquired a 56% stake in Foundation at the beginning of 2015 for $50 per share, or around $1bn, which at the time represented a whopping premium of...